var data={"title":"QT dispersion: Clinical applications","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">QT dispersion: Clinical applications</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/contributors\" class=\"contributor contributor_credentials\">Velislav Batchvarov, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/contributors\" class=\"contributor contributor_credentials\">A John Camm, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/contributors\" class=\"contributor contributor_credentials\">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/contributors\" class=\"contributor contributor_credentials\">Brian C Downey, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 15, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The QT interval duration varies between leads on the standard electrocardiogram (ECG), Frank orthogonal leads, and body surface potential maps [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/1-6\" class=\"abstract_t\">1-6</a>]. These interlead differences, called QT dispersion or QT range, were proposed as an index of the spatial dispersion of the ventricular recovery times [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/7\" class=\"abstract_t\">7</a>]. This measurement was an attempt to distinguish between myocardium that is homogeneous from myocardium that displays inhomogeneity, which is accompanied by increased dispersion of the ventricular recovery times and prolongation of repolarization. In reality, QT dispersion is a crude and approximate measure of a general abnormality of repolarization [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8\" class=\"abstract_t\">8</a>].</p><p>QT dispersion was developed in an effort to improve on ECG measures used in clinical practice, including the QT interval and its heart rate-corrected value (QTc) and the description of the ST-T morphology, often using vague terms such as &quot;non-specific ST-T wave changes.&quot; However, there has been much concern about the validity of the concept and the methodology of the measurement. Despite ongoing controversy, there are a number of reasonable conclusions about the reliability and applicability of the technique [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p>The clinical application of QT dispersion will be reviewed here. The pathophysiology and measurement of QT dispersion are discussed elsewhere. (See <a href=\"topic.htm?path=qt-dispersion-measurement-and-interpretation\" class=\"medical medical_review\">&quot;QT dispersion: Measurement and interpretation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">NORMAL VALUES AND LIMITATIONS OF QT DISPERSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reported values of QT dispersion vary widely, ranging from 10 to 71 msec in normal subjects [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8,10-13\" class=\"abstract_t\">8,10-13</a>]. In a review of 8455 healthy control subjects of various ages, including healthy children, the mean QT dispersion values ranged from 10 to 71 msec (mean 33 msec; median 37 msec) (<a href=\"image.htm?imageKey=CARD%2F75877\" class=\"graphic graphic_figure graphicRef75877 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8\" class=\"abstract_t\">8</a>]. There is little or no sex difference in QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/14-16\" class=\"abstract_t\">14-16</a>]. Age-related differences, if present, appear to be small (&lt;10 msec) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/13,17\" class=\"abstract_t\">13,17</a>].</p><p>Similar values have been noted in large studies and literature reviews that suggested that the upper normal limit of QT dispersion in normal and healthy subjects is 65 msec [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/10,18\" class=\"abstract_t\">10,18</a>]. In contrast, other reports claim that QT dispersion &gt;40 ms has a sensitivity and specificity of 88 and 57 percent, respectively, for predicting the inducibility of sustained ventricular tachycardia during an electrophysiology study [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/19\" class=\"abstract_t\">19</a>]. However, in most of the studies with positive results, values for QT dispersion are well within the demonstrated measurement error of both manual and automatic methods. Another problem is that some prospective studies only provided data for the heart rate-corrected QT (QTc) dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/20,21\" class=\"abstract_t\">20,21</a>].</p><p>QT dispersion is increased in patients with heart disease compared to healthy subjects, and prospective studies have suggested that QT dispersion has prognostic value. However, there is a great degree of overlap between healthy subjects and cardiac patients, as well as between patients with and without adverse outcomes (<a href=\"image.htm?imageKey=CARD%2F75877\" class=\"graphic graphic_figure graphicRef75877 \">figure 1</a> and <a href=\"image.htm?imageKey=CARD%2F68763\" class=\"graphic graphic_figure graphicRef68763 \">figure 2</a>). Another problem is that the reliability and reproducibility of both automatic and manual measurement of QT dispersion are low and significantly lower than that of the QT interval; the measurement error is similar to the differences among various patient groups [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"#H5\" class=\"local\">'Prognostic value of QT dispersion in normal subjects'</a> below and <a href=\"#H6\" class=\"local\">'QT dispersion in cardiac disease'</a> below and <a href=\"topic.htm?path=qt-dispersion-measurement-and-interpretation\" class=\"medical medical_review\">&quot;QT dispersion: Measurement and interpretation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">PROGNOSTIC VALUE OF QT DISPERSION IN NORMAL SUBJECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of prospective studies have assessed the predictive value of QT dispersion for cardiac and all-cause mortality in the general population [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8,20-22\" class=\"abstract_t\">8,20-22</a>]. In general, a greater amount of QT dispersion is associated with higher risk of cardiac events and mortality.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Rotterdam Study evaluated 5812 adults who were at least 55 years of age [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/20\" class=\"abstract_t\">20</a>]. After adjusting for a history of myocardial infarction, hypertension, and overall QT interval, QTc dispersion predicted cardiac mortality during a mean follow-up of four years. Compared to subjects with QTc dispersion below 39 msec, those with values above 60 msec had a higher risk of total mortality (hazard ratio [HR] 1.4), cardiac death (HR 2.5), and sudden death (HR 1.9).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the Strong Heart Study of 1839 American Indians, cardiovascular mortality was significantly higher among those with QTc dispersion values above 58 msec (HR 3.4 compared to those with QTc dispersion &lt;58 msec) (<a href=\"image.htm?imageKey=CARD%2F68172\" class=\"graphic graphic_figure graphicRef68172 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The possible prognostic importance of uncorrected QT dispersion was evaluated in a preliminary report of the WOSCOPS trial of 6595 middle-aged men with moderately raised cholesterol but no previous myocardial infarction [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/22\" class=\"abstract_t\">22</a>]. For each 10 msec increment in QT dispersion the risk of coronary death or nonfatal myocardial infarction increased by 13 percent. </p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">QT DISPERSION IN CARDIAC DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased QT dispersion has been demonstrated in patients with a variety of cardiac diseases, which is consistent with the concept that QT dispersion represents a general repolarization abnormality. However, the presence and degree of QT dispersion varies widely. This likely reflects variations in the method of measurement, interobserver variability, and other technical factors but may also result from differences in the patient groups.</p><p>Pooled data from almost 7000 patients with cardiac diseases, including acute myocardial infarction (MI), prior MI, hypertrophic cardiomyopathy, left ventricular hypertrophy (LVH) of various causes, heart failure <span class=\"nowrap\">and/or</span> idiopathic dilated cardiomyopathy, and long QT syndrome of various genotypes (<a href=\"image.htm?imageKey=CARD%2F75877\" class=\"graphic graphic_figure graphicRef75877 \">figure 1</a>) shows a clear tendency toward an increase in QT dispersion in each of these disorders [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8\" class=\"abstract_t\">8</a>]. The highest mean values occurred in patients with the long QT syndrome, which represents a global repolarization disease (<a href=\"image.htm?imageKey=CARD%2F68172\" class=\"graphic graphic_figure graphicRef68172 \">figure 3</a>). In addition, preliminary data has suggested that an increase in QT dispersion is a marker for the development of transplant vasculopathy [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-cardiac-allograft-vasculopathy\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy&quot;</a>.)</p><p>However, the great overlap of values between patients with different cardiac diseases, between patients and normal subjects, and the wide variation of values within each cardiac disease prevents the establishment of reference values. Part of the variation results from the inclusion of patients with and without arrhythmias who are taking different medications.</p><p>Despite these limitations, some general conclusions can be made from these data:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion is increased in acute MI compared to normals, although mean values from 40 to 162 ms have been described [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Some, but not all studies have found that QT dispersion is also increased in the chronic phase of MI and in chronic coronary heart disease compared to normals. However, the values are lower when compared to the acute phase of MI, possibly due to spontaneous dynamic changes or to the use of revascularization procedures [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/26,27\" class=\"abstract_t\">26,27</a>]. QT dispersion is increased in post-MI diabetic patients with compared to those post-MI patients without type 2 diabetes [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/28\" class=\"abstract_t\">28</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion is increased in patients with heart failure and left ventricular dysfunction of various causes compared to normals [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/29-32\" class=\"abstract_t\">29-32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion is increased in patients with hypertrophic cardiomyopathy and left ventricular hypertrophy of other causes, particularly hypertension [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/33-43\" class=\"abstract_t\">33-43</a>]. There are conflicting data as to whether physiologic hypertrophy resulting from physical training in well-trained athletes is or is not associated with increased QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/44-47\" class=\"abstract_t\">44-47</a>]. Androgen use may be a contributing factor [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=electrocardiographic-abnormalities-and-conduction-disturbances-in-athletes\" class=\"medical medical_review\">&quot;Electrocardiographic abnormalities and conduction disturbances in athletes&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion is increased in patients with the long QT syndrome [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/48-51\" class=\"abstract_t\">48-51</a>]. (See <a href=\"topic.htm?path=congenital-long-qt-syndrome-epidemiology-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Congenital long QT syndrome: Epidemiology and clinical manifestations&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Correlation with the extent or severity of disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Attempts have been made to correlate QT dispersion with measures of extent or localization of the cardiac disease, including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infarct location &mdash; In acute myocardial infarction, QT dispersion may be greater in anterior compared to inferior infarcts [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/52-54\" class=\"abstract_t\">52-54</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Left ventricular ejection fraction [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/55,56\" class=\"abstract_t\">55,56</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The amount of viable myocardium in the infarct region [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/57\" class=\"abstract_t\">57</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The number of diseased vessels [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p>There are conflicting data concerning a possible correlation between QT dispersion and left ventricular mass index in hypertensive patients with left ventricular hypertrophy [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/59-61\" class=\"abstract_t\">59-61</a>].</p><p>QT dispersion also varies with spontaneous or induced alterations in the pathologic process in some cardiac diseases:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion seems to undergo dynamic changes during the first day and the following days of acute MI [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/25,52,62\" class=\"abstract_t\">25,52,62</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion exhibits significant spontaneous circadian variation in healthy subjects and in patients with ischemic heart disease without myocardial infarction but not in those with previous MI and in patients with heart failure [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/63,64\" class=\"abstract_t\">63,64</a>]. In all patient groups, however, the detection of significant circadian variation depends on the number of leads used for 24-hour Holter monitoring [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion increases significantly during ischemia induced by balloon inflation during angioplasty, by exercise stress testing or atrial pacing, or immediately after reperfusion with angioplasty [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/27,65-69\" class=\"abstract_t\">27,65-69</a>]. One study of 273 patients found that the presence of QT dispersion &ge;60 msec immediately after exercise could detect the presence of a significant coronary stenosis with a sensitivity and specificity of 77 and 88 percent in patients who also have significant ST segment depression and 72 and 86 percent in those without ST segment depression [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/70\" class=\"abstract_t\">70</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion decreases significantly with improvement of left ventricular contractility after an acute MI [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/71\" class=\"abstract_t\">71</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased QT dispersion is related to the presence of viable myocardium demonstrated by improved contractility during <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">dobutamine</a> stress test in patients with ischemic heart disease [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/72\" class=\"abstract_t\">72</a>]</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Improvement with therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased QT dispersion can be reversed by effective therapy of the underlying disease. A variety of examples have been described including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Correction of hypertension with regression of left ventricular hypertrophy [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/39-43\" class=\"abstract_t\">39-43</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Successful treatment of arterial hypertension with the angiotensin receptors antagonist <a href=\"topic.htm?path=telmisartan-drug-information\" class=\"drug drug_general\">telmisartan</a> [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/73\" class=\"abstract_t\">73</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coronary reperfusion with thrombolysis, angioplasty, or coronary artery bypass grafting [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/57,74-79\" class=\"abstract_t\">57,74-79</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta blocker, angiotensin converting enzyme inhibitor, or angiotensin receptor blocker therapy in heart failure [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/32,80\" class=\"abstract_t\">32,80</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta blocker therapy or left cardiac sympathetic denervation in the congenital long QT syndrome [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/48\" class=\"abstract_t\">48</a>]</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Prognostic significance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are conflicting results concerning the value of QT dispersion for predicting ventricular arrhythmias or other adverse events in patients with cardiac disease [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8,81,82\" class=\"abstract_t\">8,81,82</a>]. Data has been pooled from 23 studies involving 1831 patients with and without serious ventricular arrhythmias who had various cardiac diseases (coronary heart disease being most common) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8\" class=\"abstract_t\">8</a>]. Although most studies show significantly greater QT dispersion in patients with ventricular arrhythmias, the values overlap widely (<a href=\"image.htm?imageKey=CARD%2F75877\" class=\"graphic graphic_figure graphicRef75877 \">figure 1</a>). Furthermore, patients with adverse outcomes often had QT dispersion values well within both the measurement error and the reported range of values in healthy subjects.</p><p>Thus, the positive results can be interpreted as indicating an &quot;indifferent&quot; QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/83\" class=\"abstract_t\">83</a>]. This does not signify lack of clinical importance; it does illustrate that increased QT dispersion in these cases merely signifies a general repolarization abnormality which, in the majority of (if not all) patients, is already visible from abnormal T wave morphology <span class=\"nowrap\">and/or</span> increased QT interval. Such QT dispersion does not necessitate a specific therapeutic action and does not help in risk stratification [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Postmyocardial infarction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of studies of patients with an acute or remote MI, most of them retrospective, have found that QT dispersion is greater in those with ventricular arrhythmias [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/30,84-86\" class=\"abstract_t\">30,84-86</a>]. However, this association has not been confirmed in prospective studies, in which QT dispersion was not predictive of ventricular arrhythmias early or late after an MI [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/87-91\" class=\"abstract_t\">87-91</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective series of 280 post-MI patients, none of 26 ventricular dispersion indices had any predictive value for an adverse outcome during a 32-month follow-up [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/87\" class=\"abstract_t\">87</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two additional prospective series of 708 and 700 post-MI patients evaluated the role of QT dispersion for risk stratification in cohorts treated with contemporary therapies including primary reperfusion and beta blockers [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/90,91\" class=\"abstract_t\">90,91</a>]. Over follow-up periods of 24 to 43 months, QT dispersion was not predictive of sudden or non-sudden cardiac death.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study on 142 patients with acute MI who underwent successful PTCA, QT dispersion measured before, but not 24 hours after PTCA was an independent predictor of mortality and major adverse cardiac events during a follow-up of 32 &plusmn; 19 months [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/92\" class=\"abstract_t\">92</a>].</p><p/><p>An important limitation to the measurement of QT dispersion is the absence of objective criteria for determination of the QT interval offset in ECG leads with low amplitude T waves or T waves merged with U waves. (See <a href=\"topic.htm?path=qt-dispersion-measurement-and-interpretation\" class=\"medical medical_review\">&quot;QT dispersion: Measurement and interpretation&quot;</a>.)</p><p>It has been suggested that spontaneous ventricular premature beats, which have increased T wave amplitude, might provide predictive information. This was evaluated in a series of 148 patients with remote MI; QT dispersion was measured manually in ventricular premature beats and in the last preceding sinus beat [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/93\" class=\"abstract_t\">93</a>]. The following findings were noted:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion was significantly greater in ventricular premature beats, compared to the preceding sinus beats (83 versus 74 msec, p = 0.001).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>QT dispersion in both sinus and ventricular premature beats was significantly greater in patients with, compared to those without, major arrhythmic events (sustained ventricular tachycardia, ventricular fibrillation, or sudden death).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Only QT dispersion &gt;100 msec, measured in ventricular premature beats, was an independent predictor of arrhythmic events in univariate and multivariate analysis, with a sensitivity, specificity, and positive and negative predictive value of 67, 75, 41, and 90 percent, respectively.</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Correlation with electrophysiologic studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are conflicting data as to whether QT dispersion can or cannot be used to predict inducibility of ventricular arrhythmias during electrophysiology study in patients with coronary heart disease and a history of ventricular tachyarrhythmias (<a href=\"image.htm?imageKey=CARD%2F68763\" class=\"graphic graphic_figure graphicRef68763 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/94-99\" class=\"abstract_t\">94-99</a>]. </p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Heart failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A significant correlation between QT dispersion and outcome has been suggested in patients with heart failure [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/80,100-102\" class=\"abstract_t\">80,100-102</a>]. However, this association has not been confirmed in sub-studies of the DIAMOND-CHF study involving <a href=\"topic.htm?path=dofetilide-drug-information\" class=\"drug drug_general\">dofetilide</a>, the UK-HEART study, and in a prospective series of 2263 patients [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/103-105\" class=\"abstract_t\">103-105</a>]. In patients with heart failure enrolled in the DIAMOND-CHF study, changes in QT dispersion following treatment with dofetilide did not predict all-cause or cardiac mortality [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/106\" class=\"abstract_t\">106</a>]. In another study on 179 consecutive patients with idiopathic dilated cardiomyopathy without sustained VT or VF at enrollment, QT dispersion did not show any predictive value for major arrhythmic events (nine patients with sudden cardiac death and 15 with sustained VT or VF) during a mean follow-up of 39 months [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/107\" class=\"abstract_t\">107</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Left ventricular hypertrophy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, correction of hypertension with regression of left ventricular hypertrophy is associated with improvement in QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/39-43\" class=\"abstract_t\">39-43</a>]. However, there is no evidence that increased QT dispersion was an independent predictive value for sudden cardiac death and cardiac mortality in these patients [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/108\" class=\"abstract_t\">108</a>]. (See <a href=\"topic.htm?path=left-ventricular-hypertrophy-and-arrhythmia\" class=\"medical medical_review\">&quot;Left ventricular hypertrophy and arrhythmia&quot;</a> and <a href=\"topic.htm?path=clinical-implications-and-treatment-of-left-ventricular-hypertrophy-in-hypertension\" class=\"medical medical_review\">&quot;Clinical implications and treatment of left ventricular hypertrophy in hypertension&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Hypertrophic cardiomyopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are conflicting data as to whether patients with hypertrophic cardiomyopathy with ventricular arrhythmias have a significant increase in QT dispersion compared to those without arrhythmias. Some small studies noted such an association, which was not confirmed in larger series [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/33,109-112\" class=\"abstract_t\">33,109-112</a>]. (See <a href=\"topic.htm?path=hypertrophic-cardiomyopathy-assessment-and-management-of-ventricular-arrhythmias-and-sudden-cardiac-death-risk\" class=\"medical medical_review\">&quot;Hypertrophic cardiomyopathy: Assessment and management of ventricular arrhythmias and sudden cardiac death risk&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Long QT syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, QT dispersion is increased in patients with long QT syndrome [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/48-51\" class=\"abstract_t\">48-51</a>]. This increase in QT dispersion can be reversed with beta blockers or left cardiac sympathetic blockade in patients with congenital disease [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/48\" class=\"abstract_t\">48</a>]. In a report on the latter, patients not responding to beta blockers had significantly greater QT dispersion than responders (137 versus 75 msec, p&lt;0.05) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/48\" class=\"abstract_t\">48</a>]. However, there are no other data that QT dispersion has prognostic value in these patients.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">EFFECT OF CARDIAC RESYNCHRONIZATION THERAPY ON QT DISPERSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiac resynchronization therapy (CRT) with biventricular pacing is used to improve symptoms and survival in patients with medically refractory advanced heart failure, nonischemic or ischemic cardiomyopathy, and left ventricular dyssynchrony. The use of CRT is discussed in detail separately. (See <a href=\"topic.htm?path=cardiac-resynchronization-therapy-in-heart-failure-indications\" class=\"medical medical_review\">&quot;Cardiac resynchronization therapy in heart failure: Indications&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 75 patients with advanced heart failure treated with CRT, QT dispersion was measured before and 48 hours after commencement of biventricular pacing [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/113\" class=\"abstract_t\">113</a>]. Pacing-induced increase in QT dispersion was a strong predictor of major arrhythmic events during an average follow-up of 807 days, independent of NYHA class, left ventricular (LV) ejection fraction, LV end-systolic and end-diastolic volume and QRS duration.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another study on 26 heart failure patients who underwent CRT, those who responded to therapy by &ge;1 NYHA association class improvement three months after CRT (n = 18) had significantly larger QTc dispersion before CRT compared to nonresponders (n = 8). Following CRT, QTc dispersion decreased significantly in responders, but not in nonresponders [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/114\" class=\"abstract_t\">114</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Conversely, in a study on 70 consecutive heart failure patients (37 with ischemic heart disease) with a history of syncope or sustained ventricular arrhythmias who underwent implantation of a biventricular pacemaker with implantable cardioverter-defibrillator (ICD), QT dispersion measured 30 days after implantation was not significantly different from the pre-procedure values, and was not predictive of appropriate ICD therapy (experienced in 39 percent of the patients during a follow-up of one year) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/115\" class=\"abstract_t\">115</a>]. Another study on 100 heart patients who have received CRT-ICD implantation also failed to show decrease in QT dispersion following device implantation both in patients with broad as well as in those narrow QRS complex, as well as any association between QT dispersion and appropriate ICD therapy (experienced in 22 patients) during a 12-month follow-up [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/116\" class=\"abstract_t\">116</a>]. </p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">EFFECT OF DRUGS ON QT DISPERSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most frequently used antiarrhythmic drugs for the treatment of cardiac arrhythmias are the class IA and class III agents (<a href=\"image.htm?imageKey=CARD%2F56600\" class=\"graphic graphic_table graphicRef56600 \">table 1</a>), whose antiarrhythmic and potentially proarrhythmic effects are thought to occur via modification of ventricular repolarization. It is becoming increasingly evident that a number of other cardiac and noncardiac drugs may prolong ventricular repolarization and trigger potentially fatal torsades de pointes [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/117,118\" class=\"abstract_t\">117,118</a>]. (See <a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Definitions, causes, and pathophysiology&quot;</a>.)</p><p>Although some of these drugs also effect QT dispersion, hopes that QT dispersion could help predict the appearance of torsades de pointes have been largely unfulfilled [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/118,119\" class=\"abstract_t\">118,119</a>]. Examples of the impact of antiarrhythmic drugs on QT dispersion include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">Quinidine</a> increases QT dispersion, which, unlike the corrected QTc interval, seems to have some predictive value for development of torsades de pointes [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/120-122\" class=\"abstract_t\">120-122</a>]. (See <a href=\"topic.htm?path=major-side-effects-of-class-i-antiarrhythmic-drugs\" class=\"medical medical_review\">&quot;Major side effects of class I antiarrhythmic drugs&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=sotalol-drug-information\" class=\"drug drug_general\">Sotalol</a> has a variable effect on QT dispersion in patients with ischemic heart disease [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/123,124\" class=\"abstract_t\">123,124</a>]. However, in one study of 61 patients who received sotalol for ventricular tachycardia <span class=\"nowrap\">and/or</span> ventricular fibrillation, QT dispersion was significantly increased in the 11 patients who developed torsades de pointes compared to those who did not [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/125\" class=\"abstract_t\">125</a>]. (See <a href=\"topic.htm?path=therapeutic-use-and-major-side-effects-of-sotalol\" class=\"medical medical_review\">&quot;Therapeutic use and major side effects of sotalol&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In general, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a> either decreases or produces no change in QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/120,121,124,126-128\" class=\"abstract_t\">120,121,124,126-128</a>]. In addition, anecdotal reports suggest that amiodarone can be safely administered to patients who have experienced torsades de pointes during therapy with other drugs; this effect is paralleled by a decrease of QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/121,129\" class=\"abstract_t\">121,129</a>]. However, amiodarone can increase QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/130\" class=\"abstract_t\">130</a>]. Amiodarone also increased QT dispersion and QTc in a preliminary report from the Canadian Implantable Defibrillator Study of patients with ventricular tachycardia, ventricular fibrillation, or syncope that was deemed to be secondary to arrhythmia; despite this change, amiodarone therapy was associated with low mortality [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/131\" class=\"abstract_t\">131</a>]. (See <a href=\"topic.htm?path=amiodarone-monitoring-and-management-of-side-effects\" class=\"medical medical_review\">&quot;Amiodarone: Monitoring and management of side effects&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=propafenone-drug-information\" class=\"drug drug_general\">Propafenone</a>, <a href=\"topic.htm?path=disopyramide-drug-information\" class=\"drug drug_general\">disopyramide</a>, and almokalant increase QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/132-134\" class=\"abstract_t\">132-134</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dofetilide-drug-information\" class=\"drug drug_general\">Dofetilide</a> does not appear to increase QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/135,136\" class=\"abstract_t\">135,136</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Azimilide and magnesium significantly decrease QT and QTc dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/137,138\" class=\"abstract_t\">137,138</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta blockers appear to reduce QT dispersion in the long QT syndrome, syndrome X (angina pectoris with normal coronary arteries), and heart failure according to some studies [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/32,48,139-141\" class=\"abstract_t\">32,48,139-141</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta blockers do not appear to reduce QT dispersion in hypertrophic cardiomyopathy [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One randomized, double-blind, cross-over study on eight patients with heart failure treated with <a href=\"topic.htm?path=losartan-drug-information\" class=\"drug drug_general\">losartan</a> alone, <a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">spironolactone</a> with an ACE-inhibitor, or losartan with spironolactone demonstrated that all three regimens significantly decreased QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/142\" class=\"abstract_t\">142</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atorvastatin-drug-information\" class=\"drug drug_general\">Atorvastatin</a> appears to shorten QTc dispersion in patients with heart failure secondary to ischemic heart disease [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/143\" class=\"abstract_t\">143</a>].</p><p/><p>Despite the evident impact of these drugs on QT dispersion, and limited evidence that patients with history of drug-induced torsades de pointes <span class=\"nowrap\">and/or</span> QT prolongation have increased QT dispersion [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/144,145\" class=\"abstract_t\">144,145</a>], the majority of data do not support the predictive value of QT dispersion for drug-induced torsades de pointes [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/119\" class=\"abstract_t\">119</a>]. In a report of 27 patients with acquired long QT syndrome, those with history of torsades de pointes (n = 12) had significantly longer QT dispersion compared to those without torsades de pointes (n = 15) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/144\" class=\"abstract_t\">144</a>]. Logistic regression analysis, however, found that QT dispersion was not a predictor of torsades de pointes. Some authors recommend abnormally prolonged QT dispersion (&gt;80 ms) to be used as an additional ECG predictor of increased risk of drug-induced torsades de pointes [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/146\" class=\"abstract_t\">146</a>]. However, in the scientific statement for prevention of torsades de pointes in hospital settings by the American Heart Association and the American College of Cardiology published in 2010, QT dispersion is not even mentioned among the ECG parameters that could be useful for monitoring the risk of torsades de pointes [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/147\" class=\"abstract_t\">147</a>].</p><p>Reasons for the discrepancy between changes in QT dispersion and the development of torsades de pointes are not clear. Experimental studies using arterially perfused ventricular wedge preparations have shown that the risk of drug-induced torsades de pointes is closely related to enhancement of the normally existing transmural dispersion of repolarization rather than to prolongation of ventricular repolarization (ie, the QT interval) [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/148-151\" class=\"abstract_t\">148-151</a>].</p><p>These studies have shown that the interval from the peak to the end of the T wave (Tpe = Tpeak - Tend) reflects transmural dispersion of repolarization [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/152\" class=\"abstract_t\">152</a>]. Thus, unlike QT dispersion, the use of the Tpe interval as a surface ECG index of dispersion of ventricular repolarization is supported by credible experimental evidence. (See <a href=\"topic.htm?path=qt-dispersion-measurement-and-interpretation#H12\" class=\"medical medical_review\">&quot;QT dispersion: Measurement and interpretation&quot;, section on 'Transmural dispersion and the Tpe interval'</a>.)</p><p>However, further research on the Tpe interval is necessary to clarify its physiological background, optimal methods of measurement (eg, in which and how many leads, etc) and clinical use. The magnitude of regional and transmural dispersion of repolarization in the beating heart under normal and abnormal conditions as opposed to the wedge preparations (which measure) are also not clear and are subject to an ongoing debate [<a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/153\" class=\"abstract_t\">153</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The QT interval duration varies between leads on the standard electrocardiogram (ECG), Frank orthogonal leads, and body surface potential maps. The variation between the longest and shortest QT intervals is reported as QT dispersion. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reported normal values of QT dispersion vary widely, and there is a great degree of overlap between healthy subjects and cardiac patients, as well as between patients with and without adverse outcomes. The lack of a standardized normal range and the overlap in values between healthy patients and those with cardiac disease has significantly limited the utility of QT dispersion in the clinical setting. (See <a href=\"#H2\" class=\"local\">'Normal values and limitations of QT dispersion'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased QT dispersion has been demonstrated in patients with a variety of cardiac diseases (eg, myocardial infarction, heart failure, long QT syndrome, etc), which is consistent with the concept that QT dispersion represents a general repolarization abnormality. However, given significant variability in QT dispersion within patients with a specific disorder, along with the marked overlap in values with healthy patients, the diagnostic and prognostic utility of QT dispersion for a specific cardiac disorder remains undetermined. (See <a href=\"#H6\" class=\"local\">'QT dispersion in cardiac disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Only significantly abnormal values of QT dispersion (ie, &gt;100 msec) which are clearly outside the possible measurement error can be recommended for use as markers of generally abnormal repolarization. However, the likelihood of finding such extreme values in ECGs from patients with normal T wave morphology is uncertain, and it is unknown if QT dispersion will offer any additional information to the traditional description of the T wave. (See <a href=\"#H6\" class=\"local\">'QT dispersion in cardiac disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>New parameters of ventricular repolarization have been developed, such as the Tpe interval, quantitative analysis of T wave morphology, and beat-to-beat QT interval variability. These parameters, which more directly reflect the electrophysiological substrate of ventricular arrhythmias, have better measurement properties, and seem to be better predictors of adverse clinical events than QT dispersion. (See <a href=\"#H17\" class=\"local\">'Effect of drugs on QT dispersion'</a> above and <a href=\"topic.htm?path=qt-dispersion-measurement-and-interpretation#H12\" class=\"medical medical_review\">&quot;QT dispersion: Measurement and interpretation&quot;, section on 'Transmural dispersion and the Tpe interval'</a>.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/1\" class=\"nounderline abstract_t\">Wilson, FN, Macleod, et al. Determination of the significance of the areas of the ventricular deflections of the electrocardiogram. Am Heart J 1934; 10:46.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/2\" class=\"nounderline abstract_t\">Rudehill A, Sundqvist K, Sylv&eacute;n C. QT and QT-peak interval measurements. A methodological study in patients with subarachnoid haemorrhage compared to a reference group. Clin Physiol 1986; 6:23.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/3\" class=\"nounderline abstract_t\">Campbell RW, Gardiner P, Amos PA, et al. Measurement of the QT interval. Eur Heart J 1985; 6 Suppl D:81.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/4\" class=\"nounderline abstract_t\">Cowan JC, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61:83.</a></li><li class=\"breakAll\">Butrous GS, Dabbas N, Patel PR, et al. Measurement of the QT Interval. In: Clinical Aspects of Ventricular Repolarization, Butrous GS, Schwartz PJ (Eds), Farrand Press, London 1989. p.41.</li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/6\" class=\"nounderline abstract_t\">Mirvis DM. Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction. J Am Coll Cardiol 1985; 5:625.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/7\" class=\"nounderline abstract_t\">Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63:342.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/8\" class=\"nounderline abstract_t\">Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36:1749.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/9\" class=\"nounderline abstract_t\">Rautaharju PM. QT and dispersion of ventricular repolarization: the greatest fallacy in electrocardiography in the 1990s. Circulation 1999; 99:2477.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/10\" class=\"nounderline abstract_t\">Surawicz B. Will QT dispersion play a role in clinical decision-making? J Cardiovasc Electrophysiol 1996; 7:777.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/11\" class=\"nounderline abstract_t\">Kautzner J, Malik M. QT interval dispersion and its clinical utility. Pacing Clin Electrophysiol 1997; 20:2625.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/12\" class=\"nounderline abstract_t\">Statters DJ, Malik M, Ward DE, Camm AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994; 5:672.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/13\" class=\"nounderline abstract_t\">Macfarlane PW, McLaughlin SC, Rodger JC. Influence of lead selection and population on automated measurement of QT dispersion. Circulation 1998; 98:2160.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/14\" class=\"nounderline abstract_t\">Tutar HE, Ocal B, Imamoglu A, Atalay S. Dispersion of QT and QTc interval in healthy children, and effects of sinus arrhythmia on QT dispersion. Heart 1998; 80:77.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/15\" class=\"nounderline abstract_t\">Challapalli, S, Lingamneni, et al. Twelve-lead QT dispersion is smaller in women than in men. Ann Noninvas Electrocardiol 1998; 3:25.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/16\" class=\"nounderline abstract_t\">Savelieva, I, Camm, et al. Gender-specific differences on QT dispersion measured in 1100 healthy subjects (abstract). Pacing Clin Electrophysiol 1999; 22:885.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/17\" class=\"nounderline abstract_t\">Savelieva, I, Camm, et al. Do we need age-adjustment of QT dispersion? Observations from 1096 normal subjects (abstract). Heart 1999; 81:P47.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/18\" class=\"nounderline abstract_t\">Zaidi M, Robert A, Fesler R, et al. Dispersion of ventricular repolarisation: a marker of ventricular arrhythmias in patients with previous myocardial infarction. Heart 1997; 78:371.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/19\" class=\"nounderline abstract_t\">Goldner B, Brandspiegel HZ, Horwitz L, et al. Utility of QT dispersion combined with the signal-averaged electrocardiogram in detecting patients susceptible to ventricular tachyarrhythmia. Am J Cardiol 1995; 76:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/20\" class=\"nounderline abstract_t\">de Bruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97:467.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/21\" class=\"nounderline abstract_t\">Okin PM, Devereux RB, Howard BV, et al. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study. Circulation 2000; 101:61.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/22\" class=\"nounderline abstract_t\">Macfarlane, PW . QT dispersion &mdash; Lack of discriminating power (abstract). Circulation 1998; 98:I81.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/23\" class=\"nounderline abstract_t\">Ali A, Mehra MR, Malik FS, et al. Insights into ventricular repolarization abnormalities in cardiac allograft vasculopathy. Am J Cardiol 2001; 87:367.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/24\" class=\"nounderline abstract_t\">Shah CP, Thakur RK, Reisdorff EJ, et al. QT dispersion may be a useful adjunct for detection of myocardial infarction in the chest pain center. Am Heart J 1998; 136:496.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/25\" class=\"nounderline abstract_t\">Glancy JM, Garratt CJ, de Bono DP. Dynamics of QT dispersion during myocardial infarction and ischaemia. Int J Cardiol 1996; 57:55.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/26\" class=\"nounderline abstract_t\">Ashikaga T, Nishizaki M, Arita M, et al. Effect of dipyridamole on QT dispersion in vasospastic angina pectoris. Am J Cardiol 1999; 84:807.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/27\" class=\"nounderline abstract_t\">Sporton SC, Taggart P, Sutton PM, et al. Acute ischaemia: a dynamic influence on QT dispersion. Lancet 1997; 349:306.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/28\" class=\"nounderline abstract_t\">Sakabe K, Fukuda N, Fukuda Y, et al. QT-interval dispersion in type 2 diabetic and non-diabetic patients with post-myocardial infarction. Nutr Metab Cardiovasc Dis 2008; 18:121.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/29\" class=\"nounderline abstract_t\">Fei L, Goldman JH, Prasad K, et al. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J 1996; 17:258.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/30\" class=\"nounderline abstract_t\">Pye M, Quinn AC, Cobbe SM. QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? Br Heart J 1994; 71:511.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/31\" class=\"nounderline abstract_t\">Zaidi M, Robert A, Fesler R, et al. Dispersion of ventricular repolarization in dilated cardiomyopathy. Eur Heart J 1997; 18:1129.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/32\" class=\"nounderline abstract_t\">Bonnar CE, Davie AP, Caruana L, et al. QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. Heart 1999; 81:297.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/33\" class=\"nounderline abstract_t\">Yi G, Elliott P, McKenna WJ, et al. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 1998; 82:1514.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/34\" class=\"nounderline abstract_t\">Calo, L, Sciarra, et al. QT dispersion and late potentials in hypertrophic cardiomyopathy (abstract). J Am Coll Cardiol 1996; 27:59A.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/35\" class=\"nounderline abstract_t\">Dritsas A, Sbarouni E, Gilligan D, et al. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992; 15:739.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/36\" class=\"nounderline abstract_t\">Zaidi M, Robert A, Fesler R, et al. Dispersion of ventricular repolarization in hypertrophic cardiomyopathy. J Electrocardiol 1996; 29 Suppl:89.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/37\" class=\"nounderline abstract_t\">Ichkhan K, Molnar J, Somberg J. Relation of left ventricular mass and QT dispersion in patients with systematic hypertension. Am J Cardiol 1997; 79:508.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/38\" class=\"nounderline abstract_t\">Perki&ouml;m&auml;ki JS, Ik&auml;heimo MJ, Pikkuj&auml;ms&auml; SM, et al. Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. Hypertension 1996; 28:16.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/39\" class=\"nounderline abstract_t\">Mayet J, Shahi M, McGrath K, et al. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension 1996; 28:791.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/40\" class=\"nounderline abstract_t\">Lim PO, Nys M, Naas AA, et al. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999; 33:713.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/41\" class=\"nounderline abstract_t\">Karpanou EA, Vyssoulis GP, Psichogios A, et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998; 136:765.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/42\" class=\"nounderline abstract_t\">Gonz&aacute;lez-Juanatey JR, Garc&iacute;a-Acu&ntilde;a JM, Pose A, et al. Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol 1998; 81:170.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/43\" class=\"nounderline abstract_t\">Tomiyama H, Doba N, Fu Y, et al. Left ventricular geometric patterns and QT dispersion in borderline and mild hypertension: their evolution and regression. Am J Hypertens 1998; 11:286.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/44\" class=\"nounderline abstract_t\">Muir, DF, Love, et al. Athletic left ventricular hypertrophy is associated with increased QT dispersion: An observational study (abstract). J Am Coll Cardiol 1999; 33:510A.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/45\" class=\"nounderline abstract_t\">Stolt A, Karila T, Viitasalo M, et al. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol 1999; 84:364.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/46\" class=\"nounderline abstract_t\">Halle M, Huonker M, Hohnloser SH, et al. QT dispersion in exercise-induced myocardial hypertrophy. Am Heart J 1999; 138:309.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/47\" class=\"nounderline abstract_t\">Mayet J, Kanagaratnam P, Shahi M, et al. QT dispersion in athletic left ventricular hypertrophy. Am Heart J 1999; 137:678.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/48\" class=\"nounderline abstract_t\">Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994; 89:1681.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/49\" class=\"nounderline abstract_t\">Gavrilescu S, Luca C. Right ventricular monophasic action potentials in patients with long QT syndrome. Br Heart J 1978; 40:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/50\" class=\"nounderline abstract_t\">Bonatti V, Rolli A, Botti G. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. Eur Heart J 1983; 4:168.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/51\" class=\"nounderline abstract_t\">Zareba W, Moss AJ, Konecki J. TU wave area-derived measures of repolarization dispersion in the long QT syndrome. J Electrocardiol 1998; 30 Suppl:191.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/52\" class=\"nounderline abstract_t\">Yap, YG, Yi, et al. Dynamic changes of QT dispersion and Its relationship with clinical variables and arrhythmic events after myocardial infarction (abstract). J Am Coll Cardiol 1999; 33:107A.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/53\" class=\"nounderline abstract_t\">Paventi S, Bevilacqua U, Parafati MA, et al. QT dispersion and early arrhythmic risk during acute myocardial infarction. Angiology 1999; 50:209.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/54\" class=\"nounderline abstract_t\">Bennemeier, H, Hartmann, et al. Effects of primary angioplasty on the course of QT dispersion after myocardial infarction and its association with infarct size (abstract). Pacing Clin Electrophysiol 1999; 22:A19.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/55\" class=\"nounderline abstract_t\">Puljevic D, Smalcelj A, Durakovic Z, Goldner V. Effects of postmyocardial infarction scar size, cardiac function, and severity of coronary artery disease on QT interval dispersion as a risk factor for complex ventricular arrhythmia. Pacing Clin Electrophysiol 1998; 21:1508.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/56\" class=\"nounderline abstract_t\">Kluger, J, Hathaway, et al. Does left ventricular function influence QT dispersion in patients with previous myocardial infarction and ventricular tachyarrhythmias? (abstract). J Am Coll Cardiol 1997; 29:510A.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/57\" class=\"nounderline abstract_t\">Schneider CA, Voth E, Baer FM, et al. QT dispersion is determined by the extent of viable myocardium in patients with chronic Q-wave myocardial infarction. Circulation 1997; 96:3913.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/58\" class=\"nounderline abstract_t\">Lyras TG, Papapanagiotou VA, Foukarakis MG, et al. Evaluation of serial QT dispersion in patients with first non-Q-wave myocardial infarction: relation to the severity of underlying coronary artery disease. Clin Cardiol 2003; 26:189.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/59\" class=\"nounderline abstract_t\">Clarkson PB, Naas AA, McMahon A, et al. QT dispersion in essential hypertension. QJM 1995; 88:327.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/60\" class=\"nounderline abstract_t\">Kohno I, Takusagawa M, Yin D, et al. QT dispersion in dipper- and nondipper-type hypertension. Am J Hypertens 1998; 11:280.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/61\" class=\"nounderline abstract_t\">Bu&#287;ra Z, Koylan N, Vural A, et al. Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Am J Hypertens 1998; 11:1164.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/62\" class=\"nounderline abstract_t\">Higham PD, Furniss SS, Campbell RW. QT dispersion and components of the QT interval in ischaemia and infarction. Br Heart J 1995; 73:32.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/63\" class=\"nounderline abstract_t\">Hansen S, Rasmussen V, Torp-Pedersen C, Jensen GB. QT intervals and QT dispersion determined from a 12-lead 24-hour Holter recording in patients with coronary artery disease and patients with heart failure. Ann Noninvasive Electrocardiol 2008; 13:22.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/64\" class=\"nounderline abstract_t\">Gunes Y, Tuncer M, Guntekin U, et al. Lack of diurnal variation of P-wave and QT dispersions in patients with heart failure. Pacing Clin Electrophysiol 2008; 31:974.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/65\" class=\"nounderline abstract_t\">Aytemir K, Bavafa V, Ozer N, et al. Effect of balloon inflation-induced acute ischemia on QT dispersion during percutaneous transluminal coronary angioplasty. Clin Cardiol 1999; 22:21.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/66\" class=\"nounderline abstract_t\">Okishige K, Yamashita K, Yoshinaga H, et al. Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty. J Am Coll Cardiol 1996; 28:70.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/67\" class=\"nounderline abstract_t\">Tarabey R, Sukenik D, Molnar J, Somberg JC. Effect of intracoronary balloon inflation at percutaneous transluminal coronary angioplasty on QT dispersion. Am Heart J 1998; 135:519.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/68\" class=\"nounderline abstract_t\">Yi G, Crook R, Guo XH, et al. Exercise-induced changes in the QT interval duration and dispersion in patients with sudden cardiac death after myocardial infarction. Int J Cardiol 1998; 63:271.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/69\" class=\"nounderline abstract_t\">Michelucci A, Padeletti L, Frati M, et al. Effects of ischemia and reperfusion on QT dispersion during coronary angioplasty. Pacing Clin Electrophysiol 1996; 19:1905.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/70\" class=\"nounderline abstract_t\">Koide Y, Yotsukura M, Yoshino H, Ishikawa K. Usefulness of QT dispersion immediately after exercise as an indicator of coronary stenosis independent of gender or exercise-induced ST-segment depression. Am J Cardiol 2000; 86:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/71\" class=\"nounderline abstract_t\">Gabrielli F, Balzotti L, Bandiera A. QT dispersion variability and myocardial viability in acute myocardial infarction. Int J Cardiol 1997; 61:61.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/72\" class=\"nounderline abstract_t\">Moreno V, Mar&iacute;n F, Monmeneu JV, de la Morena G. QT-interval dispersion and myocardial viability. Rev Esp Cardiol 2009; 62:461.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/73\" class=\"nounderline abstract_t\">Galetta F, Franzoni F, Fallahi P, et al. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother 2010; 64:516.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/74\" class=\"nounderline abstract_t\">Moreno FL, Villanueva T, Karagounis LA, Anderson JL. Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. TEAM-2 Study Investigators. Circulation 1994; 90:94.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/75\" class=\"nounderline abstract_t\">Karagounis LA, Anderson JL, Moreno FL, Sorensen SG. Multivariate associates of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct-related artery. TEAM-3 Investigators. Third trial of Thrombolysis with Eminase in Acute Myocardial Infarction. Am Heart J 1998; 135:1027.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/76\" class=\"nounderline abstract_t\">Kelly RF, Parillo JE, Hollenberg SM. Effect of coronary angioplasty on QT dispersion. Am Heart J 1997; 134:399.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/77\" class=\"nounderline abstract_t\">Szydlo K, Trusz-Gluza M, Drzewiecki J, et al. Correlation of heart rate variability parameters and QT interval in patients after PTCA of infarct related coronary artery as an indicator of improved autonomic regulation. Pacing Clin Electrophysiol 1998; 21:2407.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/78\" class=\"nounderline abstract_t\">Bonnemeier H, Hartmann F, Wiegand UK, et al. Course and prognostic implications of QT interval and QT interval variability after primary coronary angioplasty in acute myocardial infarction. J Am Coll Cardiol 2001; 37:44.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/79\" class=\"nounderline abstract_t\">Jim&eacute;nez-Candil J, Hern&aacute;ndez Hern&aacute;ndez J, Aguero VL, et al. Early reduction of QT dispersion after primary percutaneous intervention in ST-segment elevation acute myocardial infarction. Mechanisms and clinical implications. Cardiology 2009; 113:172.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/80\" class=\"nounderline abstract_t\">Brooksby P, Robinson PJ, Segal R, et al. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. Lancet 1999; 354:395.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/81\" class=\"nounderline abstract_t\">Wang CH, Chen CL, Hsiao CK, et al. Arsenic-induced QT dispersion is associated with atherosclerotic diseases and predicts long-term cardiovascular mortality in subjects with previous exposure to arsenic: A 17-Year follow-up study. Cardiovasc Toxicol 2010; 10:17.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/82\" class=\"nounderline abstract_t\">Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009; 53:426.</a></li><li class=\"breakAll\">Surawicz B. Long QT: Good, bad, indifferent and fascinating. ACC Current J Rev 1999; pp. 19-21.</li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/84\" class=\"nounderline abstract_t\">Zaputovi&#263; L, Mavri&#263; Z, Zaninovi&#263;-Jurjevi&#263; T, et al. Relationship between QT dispersion and the incidence of early ventricular arrhythmias in patients with acute myocardial infarction. Int J Cardiol 1997; 62:211.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/85\" class=\"nounderline abstract_t\">Zareba W, Moss AJ, le Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994; 74:550.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/86\" class=\"nounderline abstract_t\">Wahab A, Zaheer MS, Rabbani MU, Wahab S. A study of heart rate variability and QT dispersion in patients of acute ST elevation myocardial infarction. Indian Heart J 2009; 61:261.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/87\" class=\"nounderline abstract_t\">Zabel M, Klingenheben T, Franz MR, Hohnloser SH. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study. Circulation 1998; 97:2543.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/88\" class=\"nounderline abstract_t\">Tavernier, R, Jordaens, L . Repolarisation characteristics and sudden death after myocardial infarction: A case control study (abstract). J Am Coll Cardiol 1999; 33:146A.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/89\" class=\"nounderline abstract_t\">Aitchison JD, Campbell RW, Higham PD. Time dependent variability of QT dispersion after acute myocardial infarction and its relation to ventricular fibrillation: a prospective study. Heart 2000; 84:504.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/90\" class=\"nounderline abstract_t\">Jordaens L, Tavernier R, MIRRACLE Investigators. Determinants of sudden death after discharge from hospital for myocardial infarction in the thrombolytic era. Eur Heart J 2001; 22:1214.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/91\" class=\"nounderline abstract_t\">Huikuri HV, Tapanainen JM, Lindgren K, et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003; 42:652.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/92\" class=\"nounderline abstract_t\">Ueda H, Hayashi T, Tsumura K, et al. QT dispersion and prognosis after coronary stent placement in acute myocardial infarction. Clin Cardiol 2007; 30:229.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/93\" class=\"nounderline abstract_t\">Dabrowski A, Kramarz E, Piotrowicz R, Kubik L. Predictive power of increased QT dispersion in ventricular extrasystoles and in sinus beats for risk stratification after myocardial infarction. Circulation 2000; 101:1693.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/94\" class=\"nounderline abstract_t\">Bogun F, Chan KK, Harvey M, et al. QT dispersion in nonsustained ventricular tachycardia and coronary artery disease. Am J Cardiol 1996; 77:256.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/95\" class=\"nounderline abstract_t\">Lee KW, Okin PM, Kligfield P, et al. Precordial QT dispersion and inducible ventricular tachycardia. Am Heart J 1997; 134:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/96\" class=\"nounderline abstract_t\">Gillis AM, Traboulsi M, Hii JT, et al. Antiarrhythmic drug effects on QT interval dispersion in patients undergoing electropharmacologic testing for ventricular tachycardia and fibrillation. Am J Cardiol 1998; 81:588.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/97\" class=\"nounderline abstract_t\">Armoundas AA, Osaka M, Mela T, et al. T-wave alternans and dispersion of the QT interval as risk stratification markers in patients susceptible to sustained ventricular arrhythmias. Am J Cardiol 1998; 82:1127.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/98\" class=\"nounderline abstract_t\">Zabel, M, Klingenheben, et al. QT-dispersion does not predict inducibility or adequate device treatment in patients with malignant ventricular tachyarrhythmias (abstract). Eur Heart J 1998; 19:600.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/99\" class=\"nounderline abstract_t\">De Sutter J, Tavernier R, Van De Wiele C, et al. QT dispersion is not related to infarct size or inducibility in patients with coronary artery disease and life threatening ventricular arrhythmias. Heart 1999; 81:533.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/100\" class=\"nounderline abstract_t\">Fu GS, Meissner A, Simon R. Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J 1997; 18:281.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/101\" class=\"nounderline abstract_t\">Galinier M, Vialette JC, Fourcade J, et al. QT interval dispersion as a predictor of arrhythmic events in congestive heart failure. Importance of aetiology. Eur Heart J 1998; 19:1054.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/102\" class=\"nounderline abstract_t\">Anastasiou-Nana, MI, Nanas, et al. Dispersion od QRS and QT in patients with advanced congestive heart failure: relation to cardiac and sudden cardiac death mortality (abstract). Eur Heart J 1999; 20:117.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/103\" class=\"nounderline abstract_t\">Brendorp B, Elming H, Jun L, et al. Qt dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. Circulation 2001; 103:831.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/104\" class=\"nounderline abstract_t\">Brooksby P, Batin PD, Nolan J, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART). Eur Heart J 1999; 20:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/105\" class=\"nounderline abstract_t\">Radmanabhan, S, Amin, et al. QT dispersion has no impact on mortality in patients with moderate and severe left ventricular dysfunction: Results from a cohort of 2263 patients (abstract). J Am Coll Cardiol 1999; 33:107A.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/106\" class=\"nounderline abstract_t\">Brendorp B, Elming H, Jun L, et al. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. Eur J Heart Fail 2002; 4:201.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/107\" class=\"nounderline abstract_t\">Iacoviello M, Forleo C, Guida P, et al. Ventricular repolarization dynamicity provides independent prognostic information toward major arrhythmic events in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2007; 50:225.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/108\" class=\"nounderline abstract_t\">Galinier M, Balanescu S, Fourcade J, et al. Prognostic value of arrhythmogenic markers in systemic hypertension. Eur Heart J 1997; 18:1484.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/109\" class=\"nounderline abstract_t\">Buja G, Miorelli M, Turrini P, et al. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993; 72:973.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/110\" class=\"nounderline abstract_t\">Miorelli M, Buja G, Melacini P, et al. QT-interval variability in hypertrophic cardiomyopathy patients with cardiac arrest. Int J Cardiol 1994; 45:121.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/111\" class=\"nounderline abstract_t\">Bayrak F, Kahveci G, Mutlu B, et al. Usefulness of surface electrocardiogram in predicting the clinical course of patients with hypertrophic cardiomyopathy. Anadolu Kardiyol Derg 2007; 7 Suppl 1:178.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/112\" class=\"nounderline abstract_t\">Maron BJ, Leyhe MJ 3rd, Casey SA, et al. Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort. Am J Cardiol 2001; 87:114.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/113\" class=\"nounderline abstract_t\">Chalil S, Yousef ZR, Muyhaldeen SA, et al. Pacing-induced increase in QT dispersion predicts sudden cardiac death following cardiac resynchronization therapy. J Am Coll Cardiol 2006; 47:2486.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/114\" class=\"nounderline abstract_t\">Hina K, Kawamura H, Murakami T, et al. Association of corrected QT dispersion with symptoms improvement in patients receiving cardiac resynchronization therapy. Heart Vessels 2008; 23:325.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/115\" class=\"nounderline abstract_t\">Dilaveris P, Giannopoulos G, Synetos A, et al. Effect of biventricular pacing on ventricular repolarization and functional indices in patients with heart failure: lack of association with arrhythmic events. Europace 2009; 11:741.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/116\" class=\"nounderline abstract_t\">Lellouche N, De Diego C, Akopyan G, et al. Changes and predictive value of dispersion of repolarization parameters for appropriate therapy in patients with biventricular implantable cardioverter-defibrillators. Heart Rhythm 2007; 4:1274.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/117\" class=\"nounderline abstract_t\">Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21:1216.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/118\" class=\"nounderline abstract_t\">Moss, AJ . Drugs that prolong the QT interval: Regulatory and QT measurement issues from the United States and European perspectives. Ann Noninvas Electrocardiol 1999; 4:255.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/119\" class=\"nounderline abstract_t\">Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol 2005; 38:10.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/120\" class=\"nounderline abstract_t\">Cui G, Sager PT, Singh BN, Sen L. Different Effects of Amiodarone and Quinidine on the Homogeneity of Myocardial Refractoriness in Patients With Intraventricular Conduction Delay. J Cardiovasc Pharmacol Ther 1998; 3:201.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/121\" class=\"nounderline abstract_t\">Hii JT, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86:1376.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/122\" class=\"nounderline abstract_t\">Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995; 26:852.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/123\" class=\"nounderline abstract_t\">Day CP, McComb JM, Matthews J, Campbell RW. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991; 12:423.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/124\" class=\"nounderline abstract_t\">Cui G, Sen L, Sager P, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994; 74:896.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/125\" class=\"nounderline abstract_t\">Hohnloser, SH, van de Loo, et al. Does sotalol-induced alteration of QT-dispersion predict drug effectiveness or proarrhythmic hazards? (abstract). Circulation 1993; 88:397.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/126\" class=\"nounderline abstract_t\">Dritsas A, Gilligan D, Nihoyannopoulos P, Oakley CM. Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol 1992; 36:345.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/127\" class=\"nounderline abstract_t\">Meierhenrich R, Helguera ME, Kidwell GA, Tebbe U. Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. Int J Cardiol 1997; 60:289.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/128\" class=\"nounderline abstract_t\">Grimm W, Steder U, Menz V, et al. Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events. Clin Cardiol 1997; 20:107.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/129\" class=\"nounderline abstract_t\">van de Loo A, Klingenheben T, Hohnloser SH. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects]. Z Kardiol 1994; 83:887.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/130\" class=\"nounderline abstract_t\">Tran HT, Chow MS, Kluger J. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia. Pacing Clin Electrophysiol 1997; 20:2275.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/131\" class=\"nounderline abstract_t\">Yadav, A, Paquette, et al. Amiodarone is associated with increased QT dispersion but low mortality in a CIDS cohort (abstract). Pacing Clin Electrophysiol 1999; 22:896.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/132\" class=\"nounderline abstract_t\">Faber TS, Zehender M, Krahnefeld O, et al. Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 1997; 29:561.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/133\" class=\"nounderline abstract_t\">Trusz-Gluza, M, Swiderska E, et al. Factors influencing dispersion of repolarisation under antiarrhythmic treatment (abstract). Ann Noninvas Electrocardiol 1998; 3:S18.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/134\" class=\"nounderline abstract_t\">Houltz B, Darp&ouml; B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 21:1044.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/135\" class=\"nounderline abstract_t\">Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992; 70:1432.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/136\" class=\"nounderline abstract_t\">D&eacute;molis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94:1592.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/137\" class=\"nounderline abstract_t\">Brum, J, Alkhalidi, et al. Effects of azimilide, an IKs/IKr blocking anti-arrhythmic on QT and QTc dispersion, in patients with ventricular tachycardia (VT) (abstract). Pacing Clin Electrophysiol 1999; 22:A13.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/138\" class=\"nounderline abstract_t\">Parikka H, Toivonen L, Naukkarinen V, et al. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction. Eur Heart J 1999; 20:111.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/139\" class=\"nounderline abstract_t\">Leonardo F, Fragasso G, Rosano GM, et al. Effect of atenolol on QT interval and dispersion in patients with syndrome X. Am J Cardiol 1997; 80:789.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/140\" class=\"nounderline abstract_t\">Aygul N, Ozdemir K, Duzenli MA, Aygul MU. The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. Cardiology 2009; 112:168.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/141\" class=\"nounderline abstract_t\">Mir TS, L&auml;er S, Eiselt M, et al. Effect of Carvedilol on QT Duration in Paediatric Patients with Congestive Heart Failure. Clin Drug Investig 2004; 24:9.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/142\" class=\"nounderline abstract_t\">Shehab A, Elnour AA, Struthers AD. A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovasc J Afr 2008; 19:292.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/143\" class=\"nounderline abstract_t\">Xie RQ, Cui W, Liu F, et al. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 2010; 140:255.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/144\" class=\"nounderline abstract_t\">Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003; 105:671.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/145\" class=\"nounderline abstract_t\">Chevalier P, Rodriguez C, Bontemps L, et al. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Res 2001; 50:386.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/146\" class=\"nounderline abstract_t\">Cubeddu LX. Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance. Curr Cardiol Rev 2009; 5:166.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/147\" class=\"nounderline abstract_t\">Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010; 55:934.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/148\" class=\"nounderline abstract_t\">Yan GX, Wu Y, Liu T, et al. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001; 103:2851.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/149\" class=\"nounderline abstract_t\">Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108:1027.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/150\" class=\"nounderline abstract_t\">Liu T, Brown BS, Wu Y, et al. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006; 3:948.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/151\" class=\"nounderline abstract_t\">Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15:475.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/152\" class=\"nounderline abstract_t\">Yan GX, Lankipalli RS, Burke JF, et al. Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol 2003; 42:401.</a></li><li><a href=\"https://www.uptodate.com/contents/qt-dispersion-clinical-applications/abstract/153\" class=\"nounderline abstract_t\">Taggart P, Sutton PM, Opthof T, et al. Transmural repolarisation in the left ventricle in humans during normoxia and ischaemia. Cardiovasc Res 2001; 50:454.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1027 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H19\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">NORMAL VALUES AND LIMITATIONS OF QT DISPERSION</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">PROGNOSTIC VALUE OF QT DISPERSION IN NORMAL SUBJECTS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">QT DISPERSION IN CARDIAC DISEASE</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Correlation with the extent or severity of disease</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Improvement with therapy</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Prognostic significance</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- Postmyocardial infarction</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Correlation with electrophysiologic studies</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Heart failure</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Left ventricular hypertrophy</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Hypertrophic cardiomyopathy</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Long QT syndrome</a></li></ul></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">EFFECT OF CARDIAC RESYNCHRONIZATION THERAPY ON QT DISPERSION</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">EFFECT OF DRUGS ON QT DISPERSION</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/1027|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/75877\" class=\"graphic graphic_figure\">- QT dispersion patient groups</a></li><li><a href=\"image.htm?imageKey=CARD/68763\" class=\"graphic graphic_figure\">- QT dispersion VT</a></li><li><a href=\"image.htm?imageKey=CARD/68172\" class=\"graphic graphic_figure\">- QT dispersion mortality normals</a></li></ul></li><li><div id=\"CARD/1027|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/56600\" class=\"graphic graphic_table\">- Vaughan Williams classification of antiarrhythmic drugs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">Acquired long QT syndrome: Definitions, causes, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=amiodarone-monitoring-and-management-of-side-effects\" class=\"medical medical_review\">Amiodarone: Monitoring and management of side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiac-resynchronization-therapy-in-heart-failure-indications\" class=\"medical medical_review\">Cardiac resynchronization therapy in heart failure: Indications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-implications-and-treatment-of-left-ventricular-hypertrophy-in-hypertension\" class=\"medical medical_review\">Clinical implications and treatment of left ventricular hypertrophy in hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-cardiac-allograft-vasculopathy\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-long-qt-syndrome-epidemiology-and-clinical-manifestations\" class=\"medical medical_review\">Congenital long QT syndrome: Epidemiology and clinical manifestations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=electrocardiographic-abnormalities-and-conduction-disturbances-in-athletes\" class=\"medical medical_review\">Electrocardiographic abnormalities and conduction disturbances in athletes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertrophic-cardiomyopathy-assessment-and-management-of-ventricular-arrhythmias-and-sudden-cardiac-death-risk\" class=\"medical medical_review\">Hypertrophic cardiomyopathy: Assessment and management of ventricular arrhythmias and sudden cardiac death risk</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=left-ventricular-hypertrophy-and-arrhythmia\" class=\"medical medical_review\">Left ventricular hypertrophy and arrhythmia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-class-i-antiarrhythmic-drugs\" class=\"medical medical_review\">Major side effects of class I antiarrhythmic drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=qt-dispersion-measurement-and-interpretation\" class=\"medical medical_review\">QT dispersion: Measurement and interpretation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapeutic-use-and-major-side-effects-of-sotalol\" class=\"medical medical_review\">Therapeutic use and major side effects of sotalol</a></li></ul></div></div>","javascript":null}